<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540420</url>
  </required_header>
  <id_info>
    <org_study_id>2017-11-03BHG</org_study_id>
    <secondary_id>2017-004572-62</secondary_id>
    <nct_id>NCT03540420</nct_id>
  </id_info>
  <brief_title>Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer</brief_title>
  <acronym>ACHILES</acronym>
  <official_title>A Randomized Phase II Study Comparing Atezolizumab After Concurrent Chemo-radiotherapy With Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Levanger Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Namsos Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Volda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kristiansund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ôrebro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gävle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, Lithuania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Graubünden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Freiburger Spital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Olten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spital STS AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after
      chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is
      needed. Immunotherapy represents the largest advance in cancer therapy in recent years and
      has demonstrated promising activity in SCLC. In this study we will investigate whether
      atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have

        -  completed 4 course of platinum/etoposide and thoracic radiotherapy of 45 Gy/30
           fractions, 2 fractions per day

        -  non-progression after chemo-radiotherapy

        -  ECOG performance status 0-2

      will be randomized to receive atezolizumab 1200 mg IV every 3 weeks in 12 months or standard
      of care (observation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year survival</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate during study treatment period</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>13 months after last patient completed atezolizumab therapy</time_frame>
    <description>The number of mild (grade 1-2), severe (grade 3-4) and fatal (grade 5) events during the chemoradiotherapy will be reported for the whole study cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Health related quality of life on the EORTC QLQ-C30 and LC13 questionnaires.</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
    <description>Patients will report HRQoL before and after chemoradiotherapy and then at each evaluation the first 2 years. Mean scores will be compared at each timepoint. A difference of 10 points or more is considered clinically relevant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atezolizumab after completed chemo-radiotherapy and non-progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard care after completed chemo-radiotherapy and non-progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>atezolizumab 1200 mg intravenous every 3 weeks in 12 months</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <other_name>anti-PDL1</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed small-cell lung cancer

          -  Previous radiotherapy to the thorax is allowed as long as the patient can receive TRT
             of 45 Gy.

          -  Stage I-III according to TNM v8 ineligible for surgery provided all lesions can be
             included in a tolerable radiotherapy field (&quot;limited disease&quot;)

          -  ECOG performance status 0-2

          -  Measureable disease according to the RECIST 1.1

          -  Adequate organ function defined as: (a) Serum alanine transaminase (ALT) ≤ 2.5 x upper
             limit of normal (ULN); (b) Total serum bilirubin ≤ 1.5 x ULN; (c)Absolute neutrophil
             count (ANC) ≥ 1.5 x 10 superscr 9/L; (d) Platelets ≥ 100 x 10 superscr 9/L ; (e)
             Creatinine &lt; 100 µmol/L and calculated creatinine-clearance &gt; 50 ml/min. If calculated
             creatinine-clearance is &lt; 50 ml/min, an EDTA clearance should be performed

          -  No malignant cells in pericardial or pleural fluid (at least 1 sample should be
             obtained if pleural fluid is present) If there is so little fluid that it cannot
             easily be collected, the patient is considered eligible.

          -  Pulmonary function: FEV1 &gt; 1 l or &gt; 30 % of predicted value and DLCO &gt; 30 % of
             predicted value

          -  Female patients of childbearing potential (Postmenarcheal, not postmenopausal (&gt;12
             continuous months of amenorrhea with no identified cause other than menopause), and no
             surgical sterilization) should use highly effective contraception and take active
             measures to avoid pregnancy while undergoing atezolizumab treatment and for at least 5
             months after the last dose. Birth control methods considered to be highly effective
             are listed in Appendix D of the protocol

          -  Written informed consent

        Exclusion Criteria:

          -  previous systemic therapy for SCLC or immune checkpoint blockade therapy

          -  serious concomitant systemic disorders (for example active infection, unstable
             cardiovascular disease) which in the opinion of the investigator would compromise the
             patient's ability to complete the study, or would interfere with the evaluation of the
             efficacy and safety of the study treatment

          -  lung disease requiring systemic steroids in doses of &gt;10 mg prednisolone (or
             equivalent dose of other steroid)

          -  previous allogeneic or organ transplant

          -  active or history of autoimmune disease or immune deficiency, including, but not
             limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome,
             or multiple sclerosis

          -  history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
             active pneumonitis on screening chest computed tomography (CT) scan

          -  live vaccine administered in the last 30 days

          -  active infection requiring IV antibiotics

          -  active viral hepatitis or HIV-positive

          -  conditions - medical, social, psychological - which could prevent adequate information
             and follow-up

          -  clinically active cancer other than SCLC with the exception of malignancies with a
             negligible risk of metastases or death (e.g. 5-years OS rate of &gt;90%), such as
             adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,
             localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.
             Hormonal therapy for non-metastatic prostate or breast cancer is allowed.

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torstein B Rø, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bjørn H Grønberg, MD, PhD</last_name>
    <phone>+47 47297878</phone>
    <email>bjorn.h.gronberg@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trude C Frøseth, MSc</last_name>
    <email>Trude.Camilla.Salvesen.Froseth@stolav.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Mcculloch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seppo Langer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Schytte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saulius Cicenas</last_name>
    </contact>
    <contact_backup>
      <last_name>Vaida Gedvilaite</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Aanerud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drammen sykehus - Vestre Viken</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odd Terje Brustugun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guri Hoven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Kristansund</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Gryt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Levanger</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thor Naustdal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Molde Sjukehus</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjersti Torgersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus AHUS</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Siri Glørsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Moksnes Bjaanes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Helbekkmo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Clinic at St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Henning Grønberg, md prof</last_name>
      <email>bjorn.h.gronberg@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Øyvind Yksnøy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhus</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inger Storaker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Vikström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Planck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Tsakonas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Lundin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Rothschild</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Scherz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mark</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of St. Gallen</name>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Appenzeller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Pless</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atezolizumab</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

